Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Questions concerning plasma cell leukaemia.

P Lortholary, P Casassus, V Eclache

    Nouvelle Revue Francaise D'Hematologie
    |January 1, 1992
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

    Leukemia·2022
    Same author

    Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.

    Leukemia research·2018
    Same author

    Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma.

    Advances in hematology·2014
    Same author

    Minor clone provides a reservoir for relapse in multiple myeloma.

    Leukemia·2012
    Same author

    Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.

    Leukemia·2011
    Same author

    Routine diagnostic procedures of myelodysplastic syndromes: value of a structural blood cell parameter (NEUT-X) determined by the Sysmex XE-2100™.

    International journal of laboratory hematology·2010

    Plasma cell leukaemia (PCL) is a terminal phase or aggressive variant of myeloma. CD 56 antigen characterization suggests PCL is a myeloma variant, potentially related to other leukaemic lymphomas.

    Area of Science:

    • Hematology
    • Oncology
    • Immunology

    Background:

    • Plasma cell leukaemia (PCL) is classically defined as a terminal phase of myeloma or a primary, aggressive form.
    • Primary PCL can be more precisely termed leukaemic myelomatosis.

    Discussion:

    • The CD 56 membrane antigen, crucial for malignant plasma cell adhesion in bone marrow, provides a pathogenic hypothesis for PCL.
    • PCL is now considered a variant form of myeloma.

    Key Insights:

    • CD 56 antigen's role in cytoadhesion illuminates PCL pathogenesis.
    • PCL is understood as a leukaemic manifestation of myeloma.

    Outlook:

    • Further research into PCL as a myeloma variant may refine diagnostic and therapeutic strategies.

    Related Experiment Videos

  • Investigating the relationship between PCL, acute immunoblastic-plasmoblastic leukaemia, and mature cell leukaemic lymphoma is warranted.
  • The role of the plasmacytoid monocyte in PCL requires further elucidation.